Loading…
← CockpitCompetitor Analysis › IRLA IRulya Therapeutics Inc.Open in the cockpit ↗

IRulya Therapeutics Inc.IRLACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 96
Mkt cap
$440M
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$3.69M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-79.0 pp
WACC 14.0%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$40.59
1D+5.6%
1W+5.9%
1M+0.8%
3M+26.4%
6M+87.9%
YTD-93.9%
1Y-88.7%
ATR %11.3%
Beta1.72
52w lowhigh95.5% off high

What IRulya Therapeutics does

Employees: 38

IRulya Therapeutics at a glance

Size IRulya Therapeutics (IRLA) is a United States Health Care company (Biotechnology) with a market value of $440M, the 2770th largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.59 on 18 Nov 2026.

Performance Over six months the shares gained 87.9%, against -17.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.

Capital Return on invested capital runs 79.0 points below its cost of capital (14.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026IRLA 190Peer median 81
Six months, rebased to 100: IRulya Therapeutics against the median of its 20 peers (local-currency closes).

IRulya Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$131,000-$142,000-$186,000-$322,000-$175,000
EBITDA-$64.2M-$50.3M-$36.0M-$24.3M-$49.9M
Net income-$107M-$84.0M-$56.8M-$31.4M-$51.7M
Free cash flow-$46.9M-$41.8M-$32.2M-$18.5M-$44.2M
Capital expenditure$75,000$352,000$257,000$160,000$133,000
Total debt$0$18.5M$14.8M$13.8M$453,000

Quarterly statements and history in the cockpit →

IRulya Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-40%-20%0%000710603739ARVN65891789PRTA11518025096712041960STTK6547688317DMAC476830CADL456160KMDA688163IRLA6-month return →1-month return →
Up and to the right = strong over both horizons. IRulya Therapeutics is the large dot.

IRulya Therapeutics competitors and peer comparison

How IRulya Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IRulya Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureIRLAPeer medianRank in peer set
1-month return+0.8%-12.7%2nd highest of 21
6-month return+87.9%-17.4%highest of 20
Distance from 52-week high-95.5%-39.7%lowest of 21
ROIC minus cost of capital-79.0 pp-6.0 pp3rd lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a

Questions

Which companies are IRulya Therapeutics's closest peers?
The cockpit's peer set: Berry Genomics (000710.SZ), Qingdao Vland Biotech (603739.SS), Arvinas (ARVN), EirGenix (6589.TW), Scinopharm Taiwan (1789.TW), Prothena (PRTA), Qurient (115180.KS), Qyuns Therapeutics (2509.HK).
How has IRulya Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +87.9% against -17.4% for the median peer; over one year -88.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.